17th March 2017 Kym Jacks-Bryant

Hospitalisations and re-admissions

Data from 7 UK NHS centres 1

This retrospective study investigated the impact of rifaximin-α for secondary prevention of OHE on hospital resource utilisation using real world data from 7 UK centres. 1
Mean number of emergency hospital admissions

Adapted from Orr et al. 2016

  • Relative reduction 26.1%, p=0.001
  • Absolute reduction 0.5 admissions/person/year
Mean number of emergency hospital admissions decreased from 2.1 admissions/person/year before to 1.6 admissions/person/year during rifaximin-α treatment 1

Data from the IMPRESS study 2,3

A retrospective, observational, multicentre study including 145 patients from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
Hospitalisations per patient 3 All-cause admissions

30-day re-admissions per patient 3 All-cause admissions

In UK clinical practice, treatment with rifaximin-α was associated with significant reductions in hospitalisations per patient at 6 months and 12 months. 2

 

Safety

  • 4% patients (9/145) reported adverse drug reactions (ADRs)
  • 4/9 of these patients had C difficile infection and none discontinued treatment
  • No serious ADRs were reported
UK/XIF5/0719/0523  DOP: October 2019

Norgine Pharmaceuticals Limited. Norgine House, Widewater Place, Moorhall Road, Uxbridge, Middlesex, UB9 6NS. Company number 03527131.

01895 826600
http://norgine.co.uk/

© Copyright Norgine 2019
Policies

Footer smpc link
TARGAXAN smpc

Product under licence from Alfasigma S.p.A. TARGAXAN is a registered trademark of the Alfasigma group of companies, licensed to the Norgine group of companies.

NORGINE and the sail logo are registered trademarks of the Norgine group of companies.
Zerif Lite Developed by ThemeIsle

References

  1. Orr J G, Currie C J et al. Liver Int 2016;36:1295-1303
  2. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792
  3. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792 Supplementary Material
Seven UK participating centres agreed a standardised data collection pro-forma. Patients with chronic liver disease who were treated with rifaximin-α for secondary prevention of overt hepatic encephalopathy (OHE) were included.* Details of all causes of HE and emergency hospital admissions were requested at 3, 6 and 12 months before and after rifaximin-α initiation. Clinical data were recorded at baseline, at 3, 6 and 12 months before and after rifaximin-α initiation.
87% of patients (n=282) were taking concomitant lactulose.
*Some patients included were on 3 x 400 mg daily as this was prior to the launch of the UK licensed dose of TARGAXAN® 550 mg twice a day.

A retrospective, observational, multicentre study including 145 patients from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
INCLUSION CRITERIA: Clinical diagnosis of HE. HE diagnosed prior to rifaximin-α initiation. Initiated on rifaximin-α at least 12 months prior data collection.
EXCLUSION CRITERIA: Rifaximin-α initiated at other hospitals. Medical records unavailable.

Details of hospitalisations and hospital visits were extracted from NHS Trust electronic databases. Analysis included only alive patients at the end of 6 and 12 month periods.
IMPRESS study was sponsored and funded by Norgine

Rifaximin-α initiation dose was 1100mg/day (licensed dose) in 30%, 1200 mg/day in 64%, and other doses in 6% of patients, respectively.
This study included patients started on rifaximin-a prior to the launch of TARGAXAN® 550mg bd. 82% of patients (n=119) were taking concomitant lactulose at baseline.